melanocortin receptors is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Also, more strongly adsorbing Alums may paradoxically generate a weaker response, possibly because not enough antigen is being shown to the immune system. Al can trigger dendritic cells and other immune cells to secrete Interleukin 1 beta (IL‑1β), an immune signal that promotes antibody production. Al adheres to the cell's plasma membrane and rearranges certain lipids there. Spurred into action, the dendritic cells pick up the antigen and speed to lymph nodes, where they stick tightly to a helper T cell and presumably induce an immune response. A second mechanism depends on alum killing immune cells at the injection site although researchers aren't sure exactly how alum kills these cells. It has been speculated that the dying cells release DNA which serves as an immune alarm. Some studies found that DNA from dying cells causes them to adhere more tightly to helper T cells which ultimately leads to an increased release of antibodies by B cells. No matter what the mechanism is, Al is not a perfect adjuvant because it does not work with all antigens (e.g. malaria and tuberculosis). However, recent research indicates that alum formulated in a nanoparticle form rather than microparticles can broaden the utility of alum adjuvants and promote stronger adjuvant effects. Aluminum salt adjuvants can be damaged by freezing, making the vaccine not as effective. Accidental freezing is a concern in vaccine storage, especially in places with poor cold chains.
== External links == Clinical trial number NCT02964104 for "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin 287 Once Weekly in Subjects With Type 2 Diabetes" at ClinicalTrials.gov Clinical trial number NCT04460885 for "A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)" at ClinicalTrials.gov Clinical trial number NCT04795531 for "A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)" at ClinicalTrials.gov Clinical trial number NCT04770532 for "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2)" at ClinicalTrials.gov Clinical trial number NCT04880850 for "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)" at ClinicalTrials.gov
== BDNF-AS == The genomic locus encoding BDNF is structurally complex and also encodes BDNF-antisense (BDNF-AS; also known as BDNFOS or ANTI-BDNF). BDNF-AS is a long non-coding RNA (lncRNA) transcribed from the opposite strand of the BDNF gene. This lncRNA was identified in 2005 through searches in expressed sequence tag (EST) databases and subsequent RT-PCR experiments. The gene encoding BDNF-AS is located on chromosome 11p14.1. BDNF mRNA and BDNF-AS share a common overlapping region and form double-stranded RNA (dsRNA) duplexes. BDNF-AS regulates BDNF expression and can suppress BDNF mRNA. In the human neocortex, regions with increased activity and BDNF expression exhibit reduced BDNF-AS expression. Elevated BDNF-AS levels are associated with reduced BDNF expression and have been shown to promote neurotoxicity, increase apoptosis, and decrease cell viability. Conversely, inhibiting BDNF-AS upregulates BDNF mRNA, activates BDNF-mediated signaling pathways, increases BDNF protein levels, suppresses neuronal apoptosis, and promotes neuronal outgrowth and differentiation. The BDNF-AS gene consists of 10 exons and a functional promoter upstream of exon 1. The BDNF-AS gene generates numerous distinct non-coding RNAs through alternative splicing. This diversity of spliced isoforms is a common feature of eukaryotic organisms, particularly in the nervous system. Notably, BDNF-AS is absent in rodents, although highly homologous sequences are present in the genomes of chimpanzees and rhesus monkeys, suggesting a primate/hominid evolutionary origin of BDNF-AS.
US officials said on 30 October 2025 they had identified "targets that sit at the nexus of the drug gangs and the Maduro regime", including facilities such as ports and airstrips, including military facilities, allegedly uses for drug trafficking. On 22 December, referring to the military buildup and ongoing airstrikes, Trump stated: "Soon we will be starting the same program on land." Trump announced on 29 December the first strike on a land target in Venezuela, stating that a marine facility used for loading drug boats had been hit. Trump had previously mentioned on 26 December a strike he said happened two nights earlier, likely on 24 December. Trump gave no details about the location of the facility or what entity, military or otherwise, was responsible for the strike. As of 30 December, there were no official statements from either the US or Venezuela confirming the details of any strike. CNN reported that unnamed sources said Trump was referencing a drone strike with no casualties, conducted by the CIA, with intelligence support from US military forces, on a "remote dock on the Venezuelan coast that the US government believed was being used by the Venezuelan gang Tren de Aragua to store drugs and move them onto boats for onward shipping". Other incidents in December were speculated to be land targets mentioned by Trump. Colombia's president Petro stated that the target was a factory near Maracaibo that he suspected was used by ELN to fabricate cocaine from coca paste.
== History == Beginning in 2007, the British Engineering and Physical Sciences Research Council has funded development of ribosome-like molecular assemblers. Clearly, molecular assemblers are possible in this limited sense. A technology roadmap project, led by the Battelle Memorial Institute and hosted by several U.S. National Laboratories has explored a range of atomically precise fabrication technologies, including both early-generation and longer-term prospects for programmable molecular assembly; the report was released in December, 2007. In 2008, the Engineering and Physical Sciences Research Council provided funding of £1.5 million over six years (£1,942,235.57, $2,693,808.00 in 2021) for research working towards mechanized mechanosynthesis, in partnership with the Institute for Molecular Manufacturing, amongst others. Likewise, the term "molecular assembler" has been used in science fiction and popular culture to refer to a wide range of fantastic atom-manipulating nanomachines. Much of the controversy regarding "molecular assemblers" results from the confusion in the use of the name for both technical concepts and popular fantasies. In 1992, Drexler introduced the related but better-understood term "molecular manufacturing", which he defined as the programmed "chemical synthesis of complex structures by mechanically positioning reactive molecules, not by manipulating individual atoms". This article mostly discusses "molecular assemblers" in the popular sense.
Sources: en.wikipedia.org
The skates (Rajidae, Arhynchobatidae, Anacanthobatidae) are the only rays that are oviparous. Females lay egg cases onto the sea floor after fertilization occurs in utero. While in utero, a protected case forms around the embryo which is called the egg case. Studies have been done where egg cases were removed from gravid females to ensure proper identification in regard to skate species. Egg cases have distinguishable characteristic traits that are unique to that species, thus making it a great tool for identifying a skate. The two most distinguishable features on the egg case are the keel and the absence or presence of a fibrous covering. A keel runs laterally along both sides of the outer edge of the egg case; it is a flexible structure. Keels will also run the length of the horns on some skate species. Some egg cases have broad keels (greater than 10% of the maximum egg case width) while others have narrow keels (less than 10% of the maximum egg case width). Many egg cases are covered with a layer of fiber; some will have a fine layer while others have a thick layer.
Gabapentin is a 3,3-disubstituted derivative of GABA. Therefore, it is a GABA analog, as well as a γ-amino acid. It is similar to several other compounds that collectively are called gabapentinoids. Specifically, it is a derivative of GABA with a pentyl disubstitution at the 3 position, hence, the name - gabapentin, in such a way as to form a six-membered ring. After the formation of the ring, the amine and carboxylic groups are not in the same relative positions as they are in the GABA; they are more conformationally constrained. Although it has been known for some time that gabapentin must bind to the α2δ-1 protein to act pharmacologically (see Pharmacodynamics), the three-dimensional structure of the α2δ-1 protein with gabapentin bound (or alternatively, the native amino acid, L-Isoleucine bound) has only recently been obtained by cryo-electron microscopy. A figure of this drug-bound structure is shown in the Chemistry section of the entry on gabapentinoid drugs. This study confirms other findings to show that both compounds alternatively can bind at a single extracellular site (somewhat distant from the calcium conducting pore of the voltage-gated calcium channel α1 subunit) on the calcium channel and chemotaxis domain of α2δ-1.
Well-known disorders caused by thiamine deficiency include beriberi, Wernicke–Korsakoff syndrome, optic neuropathy, Leigh's disease, African seasonal ataxia (or Nigerian seasonal ataxia), and central pontine myelinolysis. Symptoms include malaise, weight loss, irritability and confusion. In Western countries, chronic alcoholism is a risk factor for deficiency. Also at risk are older adults, persons with HIV/AIDS or diabetes, and those who have had bariatric surgery. Varying degrees of thiamine insufficiency have been associated with the long-term use of diuretics.
== Physiological effects == Catecholamines cause general physiological changes that prepare the body for physical activity (the fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system. Some drugs, like tolcapone (a central COMT-inhibitor), raise the levels of all the catecholamines. Increased catecholamines may also cause an increased respiratory rate (tachypnoea) in patients. Catecholamine is secreted into urine after being broken down, and its secretion level can be measured for the diagnosis of illnesses associated with catecholamine levels in the body. Urine testing for catecholamine is used to detect pheochromocytoma.
Sources: en.wikipedia.org
== Function == This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1B heavy chain and LC1 light chain. Gene knockout studies of the mouse microtubule-associated protein 1B gene suggested an important role in development and function of the nervous system. Two alternatively spliced transcript variants have been described.
=== Purity determination (w/w NMR) === While NMR is primarily used for structural determination, it can also be used for purity determination, provided that the structure and molecular weight of the compound is known. This technique requires the use of an internal standard of known purity. Typically this standard will have a high molecular weight to facilitate accurate weighing, but relatively few protons so as to give a clear peak for later integration e.g. 1,2,4,5-tetrachloro-3-nitrobenzene. Accurately weighed portions of the standard and sample are combined and analysed by NMR. Suitable peaks from both compounds are selected and the purity of the sample is determined via the following equation.
== Cast == Lisa Sanders — physician, narrator, and columnist for The New York Times. Angel Parker — a 23-year-old nursing student from Las Vegas, Nevada. Her symptoms include episodes of severe muscle painthat render her immobile. Sadie Gonzalez — a 7-year-old girl from Queens, New York. She suffers from hundreds of seizures daily. Physicians initially suggest removing a large part of her brain (a hemispherectomy) as a form of treatment. Willie Reyes — a 46-year-old Army veteran from Vado, New Mexico. He suffers from frequent seizures that result in memory loss and mood swings. Kamiyah Morgan — a 6-year-old girl from Vermillion, South Dakota. She has frequent fainting episodes that can happen up to 300 times a day; these cause her to temporarily go limp and unresponsive. Lashay Hamblin — a 16-year-old high school student from South Jordan, Utah. She cannot keep down any foods or liquids but does not have bulimia. Matt Lee — a 20-year-old college student from Mt. Airy, Maryland. He suffers from frequent fainting spells that occur when he feels a sense of deja vu. These fainting spells also cause his heart to momentarily stop. Joe — a 61-year-old man from Wallingford, Connecticut. He was struck with a sudden and unexplained paralysis from his waist down, leaving him paraplegic. Ann — a 42-year-old patient from Wallingford, CT. She has intermittent paralysis affecting the right side of her body. She will regain mobility but the paralysis always occurs again.
=== Fourth week (14–18 March) === On 14 March, the Taliban-run Afghan Ministry of Defense said that Taliban forces had captured a Pakistani border outpost, killing 14 soldiers and injuring 11 others. The ministry also added that they destroyed an armored tank and a military vehicle of Pakistani forces. However, Pakistani officials denied allegations made by Afghan Ministry of Defense, terming them false, fabricated and aimed at misleading the Afghan public. According to Pakistani officials, the damages and losses suffered by the Afghan Taliban and the Pakistani Taliban were being regularly documented, with related video and photographic evidence shared with the media. Elsewhere, Pakistani security forces killed six Pakistani Taliban militants in Lakki Marwat. Later that day, Pakistani officials stated that the Pakistan Air Force had carried out airstrikes on five military bases in Kandahar, including the General Directorate of Intelligence (GDI), Haibatullah Akhundzada's special forces unit, the border command, a tunnel, and a Taliban technical equipment warehouse. Pakistani officials added that the targeted military sites had been destroyed and released videos and images of the strikes in Kandahar. Locals in Kandahar told an Agence France-Presse journalist that military aircraft had flown over a mountain housing a military facility before an explosion was heard. Afghan locals sources state that Pakistani airstrikes struck a Taliban special forces facility linked to Hibatullah Akhundzada, as well as an ammunition depot and a border command center in Kandahar Province.
Although creatinine is eliminated more slowly than iohexol, it can be determined immediately in many veterinary practices photometric even without the involvement of a specialized laboratory. In advanced kidney disease, the blood count shows a decrease in the number of red blood cells and thus the hematocrit without a change in the blood pigment load and the cell sizes of the red blood cells and without signs of new blood cell formation (normochromic, normocytic, aregenerative anemia).
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.